Schedule of Segment Reporting Information, by Segment [Table Text Block] |
The following financial information represents the operating results of the reportable segments of the Company:
Three months ended January 31, 2017 |
|
Clinical Labs |
|
|
Life Sciences |
|
|
Therapeutics |
|
|
Other |
|
|
Consolidated |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical laboratory services |
|
$ |
18,837 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
$ |
18,837 |
|
Product revenues |
|
|
— |
|
|
$ |
6,983 |
|
|
|
— |
|
|
|
— |
|
|
|
6,983 |
|
Royalty and license fee income |
|
|
— |
|
|
|
440 |
|
|
|
— |
|
|
|
— |
|
|
|
440 |
|
|
|
|
18,837 |
|
|
|
7,423 |
|
|
|
— |
|
|
|
— |
|
|
|
26,260 |
|
Operating costs, expenses and legal settlements, net: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services |
|
|
11,052 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
11,052 |
|
Cost of product revenues |
|
|
— |
|
|
|
3,520 |
|
|
|
— |
|
|
|
— |
|
|
|
3,520 |
|
Research and development |
|
|
— |
|
|
|
516 |
|
|
$ |
(33 |
) |
|
|
— |
|
|
|
483 |
|
Selling, general and administrative |
|
|
5,897 |
|
|
|
2,905 |
|
|
|
— |
|
|
$ |
2,363 |
|
|
|
11,165 |
|
Provision for uncollectible accounts receivable |
|
|
594 |
|
|
|
85 |
|
|
|
— |
|
|
|
— |
|
|
|
679 |
|
Legal fee expense |
|
|
49 |
|
|
|
16 |
|
|
|
— |
|
|
|
305 |
|
|
|
370 |
|
Total operating costs, expenses and legal settlements, net |
|
|
17,592 |
|
|
|
7,042 |
|
|
|
(33 |
) |
|
|
2,668 |
|
|
|
27,269 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) |
|
|
1,245 |
|
|
|
381 |
|
|
|
33 |
|
|
|
(2,668 |
) |
|
|
(1,009 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest |
|
|
(28 |
) |
|
|
12 |
|
|
|
— |
|
|
|
95 |
|
|
|
79 |
|
Other |
|
|
17 |
|
|
|
— |
|
|
|
— |
|
|
|
7 |
|
|
|
24 |
|
Foreign exchange loss |
|
|
— |
|
|
|
(94 |
) |
|
|
— |
|
|
|
— |
|
|
|
(94 |
) |
Income (loss) before income taxes |
|
$ |
1,234 |
|
|
$ |
299 |
|
|
$ |
33 |
|
|
$ |
(2,566 |
) |
|
$ |
(1,000 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization included above |
|
$ |
394 |
|
|
$ |
501 |
|
|
$ |
— |
|
|
$ |
20 |
|
|
$ |
915 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation included in above: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services |
|
$ |
1 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
$ |
1 |
|
Selling, general and administrative |
|
|
23 |
|
|
$ |
15 |
|
|
|
— |
|
|
$ |
202 |
|
|
|
240 |
|
Total |
|
$ |
24 |
|
|
$ |
15 |
|
|
$ |
— |
|
|
$ |
202 |
|
|
$ |
241 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
$ |
175 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
175 |
|
Three months ended January 31, 2016 |
|
Clinical Labs |
|
|
Life Sciences |
|
|
Therapeutics |
|
|
Other |
|
|
Consolidated |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical laboratory services |
|
$ |
17,523 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
$ |
17,523 |
|
Product revenues |
|
|
— |
|
|
$ |
6,578 |
|
|
|
— |
|
|
|
— |
|
|
|
6,578 |
|
Royalty and license fee income |
|
|
— |
|
|
|
459 |
|
|
|
— |
|
|
|
— |
|
|
|
459 |
|
|
|
|
17,523 |
|
|
|
7,037 |
|
|
|
— |
|
|
|
— |
|
|
|
24,560 |
|
Operating costs, expenses and legal settlements, net: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services |
|
|
10,535 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
10,535 |
|
Cost of product revenues |
|
|
— |
|
|
|
3,206 |
|
|
|
— |
|
|
|
— |
|
|
|
3,206 |
|
Research and development |
|
|
— |
|
|
|
661 |
|
|
$ |
200 |
|
|
|
— |
|
|
|
861 |
|
Selling, general and administrative |
|
|
5,649 |
|
|
|
2,773 |
|
|
|
— |
|
|
$ |
2,858 |
|
|
|
11,280 |
|
Provision for uncollectible accounts receivable |
|
|
467 |
|
|
|
(8 |
) |
|
|
— |
|
|
|
— |
|
|
|
459 |
|
Legal fee expense |
|
|
57 |
|
|
|
5 |
|
|
|
— |
|
|
|
2,349 |
|
|
|
2,411 |
|
Legal settlements, net |
|
|
1,500 |
|
|
|
(13,150 |
) |
|
|
— |
|
|
|
— |
|
|
|
(11,650 |
) |
Total operating costs, expenses and legal settlements, net |
|
|
18,208 |
|
|
|
(6,513 |
) |
|
|
200 |
|
|
|
5,207 |
|
|
|
17,102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) |
|
|
(685 |
) |
|
|
13,550 |
|
|
|
(200 |
) |
|
|
(5,207 |
) |
|
|
7,458 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest |
|
|
(23 |
) |
|
|
17 |
|
|
|
— |
|
|
|
(36 |
) |
|
|
(42 |
) |
Other |
|
|
(1 |
) |
|
|
— |
|
|
|
— |
|
|
|
12 |
|
|
|
11 |
|
Foreign exchange loss |
|
|
— |
|
|
|
(388 |
) |
|
|
— |
|
|
|
— |
|
|
|
(388 |
) |
Income (loss) before income taxes |
|
$ |
(709 |
) |
|
$ |
13,179 |
|
|
$ |
(200 |
) |
|
$ |
(5,231 |
) |
|
$ |
7,039 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization included above |
|
$ |
411 |
|
|
$ |
524 |
|
|
$ |
— |
|
|
$ |
17 |
|
|
$ |
952 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation included in above: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services |
|
$ |
2 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
$ |
2 |
|
Selling, general and administrative |
|
|
9 |
|
|
$ |
5 |
|
|
|
— |
|
|
$ |
94 |
|
|
|
108 |
|
Total |
|
$ |
11 |
|
|
$ |
5 |
|
|
$ |
— |
|
|
$ |
94 |
|
|
$ |
110 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
$ |
354 |
|
|
$ |
84 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
438 |
|
Six months ended January 31, 2017 |
|
Clinical Labs |
|
|
Life Sciences |
|
|
Therapeutics |
|
|
Other |
|
|
Consolidated |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical laboratory services |
|
$ |
37,395 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
$ |
37,395 |
|
Product revenues |
|
|
— |
|
|
$ |
14,409 |
|
|
|
— |
|
|
|
— |
|
|
|
14,409 |
|
Royalty and license fee income |
|
|
— |
|
|
|
740 |
|
|
|
— |
|
|
|
— |
|
|
|
740 |
|
|
|
|
37,395 |
|
|
|
15,149 |
|
|
|
— |
|
|
|
— |
|
|
|
52,544 |
|
Operating costs, expenses and legal settlements, net: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services |
|
|
21,948 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
21,948 |
|
Cost of product revenues |
|
|
— |
|
|
|
6,829 |
|
|
|
— |
|
|
|
— |
|
|
|
6,829 |
|
Research and development |
|
|
— |
|
|
|
1,143 |
|
|
$ |
162 |
|
|
|
— |
|
|
|
1,305 |
|
Selling, general and administrative |
|
|
11,849 |
|
|
|
5,851 |
|
|
|
— |
|
|
$ |
4,939 |
|
|
|
22,639 |
|
Provision for uncollectible accounts receivable |
|
|
1,260 |
|
|
|
88 |
|
|
|
— |
|
|
|
— |
|
|
|
1,348 |
|
Legal fee expense |
|
|
101 |
|
|
|
28 |
|
|
|
— |
|
|
|
613 |
|
|
|
742 |
|
Total operating costs, expenses and legal settlements, net |
|
|
35,158 |
|
|
|
13,939 |
|
|
|
162 |
|
|
|
5,552 |
|
|
|
54,811 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) |
|
|
2,237 |
|
|
|
1,210 |
|
|
|
(162 |
) |
|
|
(5,552 |
) |
|
|
(2,267 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest |
|
|
(57 |
) |
|
|
22 |
|
|
|
— |
|
|
|
160 |
|
|
|
125 |
|
Other |
|
|
119 |
|
|
|
— |
|
|
|
— |
|
|
|
24 |
|
|
|
143 |
|
Foreign exchange loss |
|
|
— |
|
|
|
(455 |
) |
|
|
— |
|
|
|
— |
|
|
|
(455 |
) |
Income (loss) before income taxes |
|
$ |
2,299 |
|
|
$ |
777 |
|
|
$ |
(162 |
) |
|
$ |
(5,368 |
) |
|
$ |
(2,454 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization included above |
|
$ |
795 |
|
|
$ |
1,009 |
|
|
$ |
— |
|
|
$ |
38 |
|
|
$ |
1,842 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation included in above: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services |
|
$ |
3 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
$ |
3 |
|
Selling, general and administrative |
|
|
40 |
|
|
$ |
26 |
|
|
|
— |
|
|
$ |
323 |
|
|
|
389 |
|
Total |
|
$ |
43 |
|
|
$ |
26 |
|
|
$ |
— |
|
|
$ |
323 |
|
|
$ |
392 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
$ |
587 |
|
|
$ |
102 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
689 |
|
Six months ended January 31, 2016 |
|
Clinical Labs |
|
|
Life Sciences |
|
|
Therapeutics |
|
|
Other |
|
|
Consolidated |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical laboratory services |
|
$ |
34,613 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
$ |
34,613 |
|
Product revenues |
|
|
— |
|
|
$ |
14,265 |
|
|
|
— |
|
|
|
— |
|
|
|
14,265 |
|
Royalty and license fee income |
|
|
— |
|
|
|
859 |
|
|
|
— |
|
|
|
— |
|
|
|
859 |
|
|
|
|
34,613 |
|
|
|
15,124 |
|
|
|
— |
|
|
|
— |
|
|
|
49,737 |
|
Operating costs, expenses and legal settlements, net: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services |
|
|
20,867 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
20,867 |
|
Cost of product revenues |
|
|
— |
|
|
|
6,817 |
|
|
|
— |
|
|
|
— |
|
|
|
6,817 |
|
Research and development |
|
|
— |
|
|
|
1,328 |
|
|
$ |
400 |
|
|
|
— |
|
|
|
1,728 |
|
Selling, general and administrative |
|
|
10,935 |
|
|
|
5,832 |
|
|
|
— |
|
|
$ |
4,738 |
|
|
|
21,505 |
|
Provision for uncollectible accounts receivable |
|
|
1,175 |
|
|
|
(12 |
) |
|
|
— |
|
|
|
— |
|
|
|
1,163 |
|
Legal fee expense |
|
|
66 |
|
|
|
(17 |
) |
|
|
— |
|
|
|
3,963 |
|
|
|
4,012 |
|
Legal settlements, net |
|
|
1,500 |
|
|
|
(19,950 |
) |
|
|
— |
|
|
|
— |
|
|
|
(18,450 |
) |
Total operating costs, expenses and legal settlements, net |
|
|
34,543 |
|
|
|
(6,002 |
) |
|
|
400 |
|
|
|
8,701 |
|
|
|
37,642 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) |
|
|
70 |
|
|
|
21,126 |
|
|
|
(400 |
) |
|
|
(8,701 |
) |
|
|
12,095 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest |
|
|
(42 |
) |
|
|
31 |
|
|
|
— |
|
|
|
(71 |
) |
|
|
(82 |
) |
Other |
|
|
3 |
|
|
|
39 |
|
|
|
— |
|
|
|
23 |
|
|
|
65 |
|
Foreign exchange loss |
|
|
— |
|
|
|
(518 |
) |
|
|
— |
|
|
|
— |
|
|
|
(518 |
) |
Income (loss) before income taxes |
|
$ |
31 |
|
|
$ |
20,678 |
|
|
$ |
(400 |
) |
|
$ |
(8,749 |
) |
|
$ |
11,560 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization included above |
|
$ |
808 |
|
|
$ |
1,054 |
|
|
$ |
— |
|
|
$ |
40 |
|
|
$ |
1,902 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation included in above: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of clinical laboratory services |
|
$ |
3 |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
$ |
3 |
|
Selling, general and administrative |
|
|
19 |
|
|
$ |
10 |
|
|
|
— |
|
|
$ |
189 |
|
|
|
218 |
|
Total |
|
$ |
22 |
|
|
$ |
10 |
|
|
$ |
— |
|
|
$ |
189 |
|
|
$ |
221 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
$ |
791 |
|
|
$ |
152 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
943 |
|
|